Monocytes/macrophages as well as regulatory T cells localized to the TME were suggested to be essential for the progression and development of cancer by inhibiting the anti-tumor immune attack. Recruitment and localization of these regulatory cells into the tumors is regulated by chemokines such as CCL5, CCL-2, and CXCL10. The Company has developed a unique discovery platform, Chemo-Hit™, to target the combinatorial activity chemokines that are involved in trafficking of these cells into the TME.
Biokine’s second program, BKT130 is a novel antibody that targets these key chemokines. BKT130 binds to these chemokines and inhibits the chemokines’ ability to stimulate adhesion and migration of these cells into sites of tumor development and block tumor development. BKT130 is in preclinical development stage. Biokine is planning to initiate phase I/IIa clinical study in cancer patients with in the next three years.
BKT130 is protected by issued patents throughout many territories from June 2009, BKT300 is protected by pending patents as from December 2015. Composition of matter and product use in different indications are covered by patents and patent applications. With patent extensions, BKT130 composition patent will have patent coverage at least up to 2032 and BKT300 will have patent coverage until 2038.
Aberrant migration and proliferation of cancer cells are the hallmark of metastatic tumors. Using our unique discovery platform, Chemo-Hit™A the company has identified novel synthetic small molecule (400d, a 5 simple step of production process) which inhibit selectively the migration and survival of hematological as well as solid cancer cells, but not normal cells.
BKT300 selectively induces the arrest of leukemic, ovarian, pancreatic, lung, and prostate cancer cells at G2M and induces their rapid apoptotic cell death in vitro and in vivo. BKT300 had no apparent toxicity in mice injected IV with 40 mg/Kg for up to two weeks. Preliminary data indicate that BKT300 regulates key component of the cell cycle pathway which is expressed only in tumor cells. In normal cells as well as in some tumor cells that do not response to BKT300, this pathway is absent.